Review Article| Volume 34, ISSUE 1, P15-30, March 2014

Clinical Features of Heart Failure and Acute Coronary Syndromes

Published:January 16, 2014DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Go A.S.
        • Mozaffarian D.
        • Roger V.L.
        • et al.
        Heart disease and stroke statistics–2013 update: a report from the American Heart Association.
        Circulation. 2013; 127: e6-e245
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62: 1495-1539
        • Jessup M.
        • Brozena S.
        Heart failure.
        N Engl J Med. 2003; 348: 2007-2018
        • Wang C.S.
        • FitzGerald J.M.
        • Schulzer M.
        • et al.
        Does this dyspneic patient in the emergency department have congestive heart failure?.
        JAMA. 2005; 294: 1944-1956
        • Marantz P.R.
        • Tobin J.N.
        • Wassertheil-Smoller S.
        • et al.
        The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria.
        Circulation. 1988; 77: 607-612
        • Shamsham F.
        • Mitchell J.
        Essentials of the diagnosis of heart failure.
        Am Fam Physician. 2000; 61: 1319-1328
        • Stevenson L.W.
        • Perloff J.K.
        The limited reliability of physical signs for estimating hemodynamics in chronic heart failure.
        JAMA. 1989; 261: 884-888
        • Mudd J.O.
        • Kass D.A.
        Tackling heart failure in the twenty-first century.
        Nature. 2008; 451: 919-928
        • Butman S.M.
        • Ewy G.A.
        • Standen J.R.
        • et al.
        Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension.
        J Am Coll Cardiol. 1993; 22: 968-974
        • Ducas J.
        • Magder S.
        • McGregor M.
        Validity of the hepatojugular reflux as a clinical test for congestive heart failure.
        Am J Cardiol. 1983; 52: 1299-1303
        • Costello-Boerrigter L.C.
        • Boerrigter G.
        • Redfield M.M.
        • et al.
        Amino-terminal pro-b-type natriuretic peptide and b-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.
        J Am Coll Cardiol. 2006; 47: 345-353
        • Tang W.H.
        • Girod J.P.
        • Lee M.J.
        • et al.
        Plasma b-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure.
        Circulation. 2003; 108: 2964-2966
        • Januzzi Jr., J.L.
        • Rehman S.U.
        • Mohammed A.A.
        • et al.
        Use of amino-terminal pro-b-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.
        J Am Coll Cardiol. 2011; 58: 1881-1889
        • Fonarow G.C.
        • Peacock W.F.
        • Horwich T.B.
        • et al.
        Usefulness of b-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from adhere.
        Am J Cardiol. 2008; 101: 231-237
        • Januzzi Jr., J.L.
        • Peacock W.F.
        • Maisel A.S.
        • et al.
        Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study.
        J Am Coll Cardiol. 2007; 50: 607-613
        • Lok D.J.
        • Van Der Meer P.
        • de la Porte P.W.
        • et al.
        Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
        Clin Res Cardiol. 2010; 99: 323-328
        • Badgett R.G.
        • Mulrow C.D.
        • Otto P.M.
        • et al.
        How well can the chest radiograph diagnose left ventricular dysfunction?.
        J Gen Intern Med. 1996; 11: 625-634
      1. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators.
        N Engl J Med. 1992; 327: 685-691
        • Granger C.B.
        • McMurray J.J.
        • Yusuf S.
        • et al.
        Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
        Lancet. 2003; 362: 772-776
        • Pitt B.
        • Zannad F.
        • Remme W.J.
        • et al.
        The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
        N Engl J Med. 1999; 341: 709-717
        • Zannad F.
        • McMurray J.J.
        • Krum H.
        • et al.
        Eplerenone in patients with systolic heart failure and mild symptoms.
        N Engl J Med. 2011; 364: 11-21
        • Cohn J.N.
        • Archibald D.G.
        • Ziesche S.
        • et al.
        Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study.
        N Engl J Med. 1986; 314: 1547-1552
        • Taylor A.L.
        • Ziesche S.
        • Yancy C.
        • et al.
        Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
        N Engl J Med. 2004; 351: 2049-2057
        • Brophy J.M.
        • Joseph L.
        • Rouleau J.L.
        Beta-blockers in congestive heart failure. A bayesian meta-analysis.
        Ann Intern Med. 2001; 134: 550-560
      2. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
        Circulation. 1995; 92: 212-218
        • Poole-Wilson P.A.
        • Swedberg K.
        • Cleland J.G.
        • et al.
        Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial.
        Lancet. 2003; 362: 7-13
        • The Digitalis Investigation Group
        The effect of digoxin on mortality and morbidity in patients with heart failure.
        N Engl J Med. 1997; 336: 525-533
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • et al.
        Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
        N Engl J Med. 2002; 346: 877-883
        • Cleland J.G.
        • Daubert J.C.
        • Erdmann E.
        • et al.
        The effect of cardiac resynchronization on morbidity and mortality in heart failure.
        N Engl J Med. 2005; 352: 1539-1549
        • Piller L.B.
        • Baraniuk S.
        • Simpson L.M.
        • et al.
        Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
        Circulation. 2011; 124: 1811-1818
        • Thygesen K.
        • Alpert J.S.
        • White H.D.
        Universal definition of myocardial infarction.
        Eur Heart J. 2007; 28: 2525-2538
        • Thygesen K.
        • Alpert J.S.
        • Jaffe A.S.
        • et al.
        Third universal definition of myocardial infarction.
        Circulation. 2012; 126: 2020-2035
        • O'Gara P.T.
        • Kushner F.G.
        • Ascheim D.D.
        • et al.
        2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 61: 485-510
        • Canto J.G.
        • Shlipak M.G.
        • Rogers W.J.
        • et al.
        Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain.
        JAMA. 2000; 283: 3223-3229
        • Anderson J.L.
        • Adams C.D.
        • Antman E.M.
        • et al.
        ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American College Of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
        J Am Coll Cardiol. 2007; 50: e1-e157
        • Colaco R.
        • Reay P.
        • Beckett C.
        • et al.
        False positive ECG reports of anterior myocardial infarction in women.
        J Electrocardiol. 2000; 33: 239-244
        • Kulkarni A.U.
        • Brown R.
        • Ayoubi M.
        • et al.
        Clinical use of posterior electrocardiographic leads: a prospective electrocardiographic analysis during coronary occlusion.
        Am Heart J. 1996; 131: 736-741
        • Shlipak M.G.
        • Go A.S.
        • Frederick P.D.
        • et al.
        Treatment and outcomes of left bundle-branch block patients with myocardial infarction who present without chest pain. National Registry of Myocardial Infarction 2 Investigators.
        J Am Coll Cardiol. 2000; 36: 706-712
        • Adams 3rd, J.E.
        • Abendschein D.R.
        • Jaffe A.S.
        Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s?.
        Circulation. 1993; 88: 750-763
        • Eggers K.M.
        • Oldgren J.
        • Nordenskjold A.
        • et al.
        Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction.
        Am Heart J. 2004; 148: 574-581
        • Puleo P.R.
        • Guadagno P.A.
        • Roberts R.
        • et al.
        Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB.
        Circulation. 1990; 82: 759-764
        • Jaffe A.S.
        • Babuin L.
        • Apple F.S.
        Biomarkers in acute cardiac disease: the present and the future.
        J Am Coll Cardiol. 2006; 48: 1-11
        • de Lemos J.A.
        • Morrow D.A.
        • Bentley J.H.
        • et al.
        The prognostic value of b-type natriuretic peptide in patients with acute coronary syndromes.
        N Engl J Med. 2001; 345: 1014-1021
        • James S.K.
        • Lindahl B.
        • Siegbahn A.
        • et al.
        N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV substudy.
        Circulation. 2003; 108: 275-281
        • Keeley E.C.
        • Boura J.A.
        • Grines C.L.
        Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
        Lancet. 2003; 361: 13-20
      3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
        Lancet. 1988; 2: 349-360
        • Sabatine M.S.
        • Cannon C.P.
        • Gibson C.M.
        • et al.
        Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.
        JAMA. 2005; 294: 1224-1232
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • et al.
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • et al.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Bhatt D.L.
        • Lincoff A.M.
        • Califf R.M.
        • et al.
        The benefit of abciximab in percutaneous coronary revascularization is not device-specific.
        Am J Cardiol. 2000; 85: 1060-1064
        • Montalescot G.
        • Zeymer U.
        • Silvain J.
        • et al.
        Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
        Lancet. 2011; 378: 693-703
        • Stone G.W.
        • Witzenbichler B.
        • Guagliumi G.
        • et al.
        Bivalirudin during primary PCI in acute myocardial infarction.
        N Engl J Med. 2008; 358: 2218-2230
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • et al.
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • Chen Z.M.
        • Pan H.C.
        • Chen Y.P.
        • et al.
        Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
        Lancet. 2005; 366: 1622-1632
      4. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico.
        Lancet. 1994; 343: 1115-1122
        • Pfeffer M.A.
        • Braunwald E.
        • Moye L.A.
        • et al.
        Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators.
        N Engl J Med. 1992; 327: 669-677
        • Pitt B.
        • Remme W.
        • Zannad F.
        • et al.
        Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 2003; 348: 1309-1321
        • Anderson H.V.
        • Cannon C.P.
        • Stone P.H.
        • et al.
        One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
        J Am Coll Cardiol. 1995; 26: 1643-1650
        • Gray W.A.
        • Yadav J.S.
        • Verta P.
        • et al.
        The CAPTURE registry: predictors of outcomes in carotid artery stenting with embolic protection for high surgical risk patients in the early post-approval setting.
        Catheter Cardiovasc Interv. 2007; 70: 1025-1033
        • Hochman J.S.
        • Sleeper L.A.
        • Webb J.G.
        • et al.
        Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock.
        N Engl J Med. 1999; 341: 625-634
        • Antman E.M.
        • Cohen M.
        • Bernink P.J.
        • et al.
        The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making.
        JAMA. 2000; 284: 835-842